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Abstract 
Short communication on t(6;12)(q22;q14.1) 
LRIG3/ROS1 in lung adenocarcinoma with data on 
clinics. 
Clinics and pathology 
Disease 
Lung adenocarcinoma 
Epidemiology 
ROS1 translocations are found in 0.9 to 1.7% of 
non small cell lung carcinomas and the majority of 
the cases are adenocarcinoma (Bergethon et al., 
2012; Davies et al., 2012; Takeuchi et al., 2012). 
Multiple fusion partners have been identified and 
LRIG3 is one of them. As for LRIG3-ROS1, only 
one case, a 57-year-old Japanese male patient, has 
been reported to date (Takeuchi et al., 2012). 
Clinics 
The patient had a 5 pack year of smoking history 
and was diagnosed as having stage 1A lung 
adenocarcinoma. 
Pathology 
This case showed moderately differentiated 
micropapillary pattern. A mucinous cribriform 
pattern which is frequently seen in cancers with 
kinase fusions was not found. This case was 
negative for EGFR and KRAS mutations as with 
the most cases harboring ROS1 gene fusions. 
Treatment 
The primary tumor was surgically removed and the 
patient received post-operative chemotherapy with 
UFT. Although not administered in this case, 
Crizotinib and other ALK inhibitors have been 
reported to be effective in lung cancers with ROS1 
translocations (Bergethon et al., 2012; Shaw et al., 
2012). 
Prognosis 
With 5 years of follow-up, the patient was alive 
without relapse. 
Genes involved and 
proteins 
LRIG3 
Location 
12q14.1 
DNA / RNA 
Leucine-Rich Repeats And Immunoglobulin-Like 
Domains Protein 3. 
ROS1 
Location 
6q22 
DNA / RNA 
C-Ros Oncogene 1, Receptor Tyrosine Kinase. 
Result of the chromosomal 
anomaly 
Hybrid Gene 
Transcript 
LRIG3-ROS1 fusion transcript was detected. 
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A. The schematic structure of LRIG3, ROS1, and LRIG3-ROS1 proteins and the cDNA sequence around the fusion point: 
Exon 16 of LRIG3 fused to exon 35 of ROS1. The break point of ROS1 allows the resulting fusion protein to retain the kinase 
domain (red). LRIG3 contains a transmembrane domain (orange). B: RT-PCR confirmation of LRIG3-ROS1 fusion: Lane M 
and N represent the size standard (20-bp ladder) and the non-template control, respectively. C. Fusion FISH analysis: A fusion 
signal (yellow) was observed in consequence of the fusion of LRIG3 (red) and ROS1 (green). 
 
 
Detection 
A 218 bp cDNA fragment harboring the fusion 
point can be detected with LRIG3 forward primer 
(5'-ACACAGATGAGACCAACTTGC-3') and 
ROS1 reverse primer (5'-
CACTGTCACCCCTTCCTTG-3'). 
Fusion Protein 
Description 
The fusion protein encompasses the constitutive 
activation of ROS1 tyrosine kinase.  
However, the mechanism of it is largely unknown. 
The role of LRIG3 here has not been clarified. 
LRIG3 protein does not contain a coiled-coil 
domain as in the case with most of the other ROS1 
fusion partners (Takeuchi et al., 2012). 
In respect of the downstream signaling, several 
growth and survival signaling pathways which are 
common to other receptor tyrosine kinases have 
been shown to be involved.  
These include PI3K/AKT, JAK/STAT3, 
RAS/MAPK/ERK, VAV3, and SHP-1 and SHP-2 
pathways (Chin et al., 2012; Davies and Doebele, 
2013). 
Oncogenesis 
The oncogenicity of LRIG3-ROS1 fusion was 
proven in a focus formation assay and a nude 
mouse tumorigenicity assay (Takeuchi et al., 2012). 
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